4.1 Review

Epidemiology, management, and prevention of exit site infections in peritoneal dialysis patients

Journal

THERAPEUTIC APHERESIS AND DIALYSIS
Volume 26, Issue 2, Pages 275-287

Publisher

WILEY
DOI: 10.1111/1744-9987.13726

Keywords

exit site infection; peritoneal dialysis; peritonitis

Ask authors/readers for more resources

Exit site infection (ESI) is a common complication of peritoneal dialysis (PD) and is associated with a high risk of catheter removal and peritonitis. The type of bacteria causing ESI affects the risk of subsequent peritonitis, with gram-positive ESIs having a lower cure rate. Mycobacteria, Staphylococcus aureus, and Pseudomonas aeruginosa are the most common bacteria causing ESI requiring catheter removal. No specific prophylactic measures have shown clear benefits, and individualized exit site hygiene is recommended. Topical gentamicin has been found effective in preventing most ESIs, especially gram-negative ESIs.
Exit site infection (ESI) is a leading complication of peritoneal dialysis (PD), at an incidence of 0.6 episodes per year in the United States, and a major risk factor for catheter removal and peritonitis. An estimated 20% of all peritonitis cases are preceded by an ESI, with up to 50% of Staphylococcus aureus peritonitis associated with ESI. Gram-negative ESIs are less associated with succeeding peritonitis than their gram-positive counterparts, though when present, are associated with a lower peritonitis cure rate. The rate of catheter removal for refractory ESI is relatively highest in ESI due to mycobacteria (up to 40%), S. aureus (35%), Pseudomonas aeruginosa (28%), followed by Corynebacterium, Serratia, and fungi. In review of relevant literature, we found no prophylactic benefit of dressings over nondressings, specific antiseptics over normal saline, or topical honey over topical antibiotic prophylaxis, and thus recommend individualized exit site hygiene. We found topical gentamicin effective for prevention of most ESIs, including gram-negative ESIs, and thus recommend consideration of prophylactic topical gentamicin in areas of high gram-negative peritonitis incidence. With long-term use, observational studies detect up to 25% of gram-positive and 14% of gram-negative ESIs may be mupirocin and gentamicin resistant, respectively. We review empiric and targeted ESI management, including indications for ultrasound, anti-VMRSA, anti-Pseudomonal, and anti-mycobacterial antibiotic use, and catheter removal. We recommend further investigation into the earlier use of second-line treatment agents and the utility of treating post-infectious exit site colonization as avenues to decrease refractory and repeat ESI.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.1
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available